Roche’s Gazyvaro gets NICE nod for high-risk lymphoma patients
Cost regulators for NHS treatments in England and Wales have now recommended funding for Roche’s Gazyvaro for some patients with untreated follicular lymphoma, after the submission of new data by the company.
Read More
